PROCEPT BioRobotics Corporation PRCT
22.94 USD -0.11 (-0.47%)
Nov 11, 2026, 3:24 PM EST
22.55 Day range 23.23
16.67 52-week range 38.11
- YTD
- -27.08%
- 1 year
- -26.80%
Benzinga news
benzinga.com Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Hold and raises the price target from $21 to $24.
benzinga.com UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21 UBS analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral and raises the price target from $20 to $21.
benzinga.com Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Market Perform and raises the price target from $20 to $22.
benzinga.com PROCEPT BioRobotics Q3 2026 Earnings Call Transcript PROCEPT BioRobotics (NASDAQ:PRCT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $395.409 million estimate.- benzinga.com Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30 Barclays analyst Christopher Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight rating and announces Price Target of $30.
benzinga.com TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $28 TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $34 to $28.
benzinga.com Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25 Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.
benzinga.com Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23 Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.- benzinga.com William Blair Downgrades PROCEPT BioRobotics to Market Perform William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
- benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $397.424M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $397.424 million estimate.
- benzinga.com PROCEPT BioRobotics Q2 EPS $(0.47) Misses $(0.46) Estimate, Sales $94.498M Beat $92.893M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent. This is a 34.29 percent decrease over losses…
benzinga.com Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25 Truist Securities analyst Richard Newitter downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Hold and lowers the price target from $30 to $25.
benzinga.com This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Wall Street analysts upgraded various top stocks, including Nucor, Varonis, Invitation Homes, and Macerich. See what experts say about NUE.
benzinga.com This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts changed outlook on top names, see all changes on Benzinga's analyst ratings page. Check out views on BB, SLGL, PRCT, OGE, TTWO.- benzinga.com Evercore ISI Group Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $30 Evercore ISI Group analyst Vijay Kumar initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform rating and announces Price Target of $30.
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q2 Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold, according to Benzinga Pro. iRhythm, Procept Biorobotics, Anbio Biotechnology among lowest RSI values.
benzinga.com This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page and analysts' views before buying MKTX stock.- benzinga.com Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform, Lowers Price Target to $29 Leerink Partners analyst Mike Kratky downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform and lowers the price target from $31 to $29.
benzinga.com PROCEPT BioRobotics Announces Two Milestones In Its WATER IV Prostate Cancer Clinical Program PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation®…- benzinga.com Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Raises Price Target to $35 Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $28 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $396.674M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $396.674 million estimate.
- benzinga.com PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.56) per share which met the analyst consensus estimate. This is a 24.44 percent decrease over losses of $(0.45) per share from the…
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com Baird Initiates Coverage On PROCEPT BioRobotics with Neutral Rating, Announces Price Target of $30 Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $30.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $30 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $47 to $30.
benzinga.com Leerink Partners Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $30 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $55 to $30.- benzinga.com TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $34 TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $50 to $34.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $28 Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $50 to $28.
- benzinga.com Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $34 Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $51 to $34.
benzinga.com C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 sales expected at $79-82 million.
benzinga.com Forecasting The Future: 5 Analyst Projections For PROCEPT BioRobotics 
benzinga.com Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com PROCEPT BioRobotics Sees Q1 Sales $79.000M-$82.000M vs $92.646M Est PROCEPT BioRobotics (NASDAQ:PRCT) sees Q1 sales of $79.000 million-$82.000 million vs $92.646 million analyst estimate.
- benzinga.com PROCEPT BioRobotics Q4 EPS $(0.53) Misses $(0.32) Estimate, Sales $76.383M Miss $94.137M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.32) by 67.19 percent. This is a 51.43 percent decrease over losses…
- benzinga.com PROCEPT BioRobotics Lowers FY2026 Sales Guidance from $410.000M-$430.000M to $390.000M-$410.000M PROCEPT BioRobotics (NASDAQ:PRCT) lowers FY2026 sales outlook from $410.000 million-$430.000 million to $390.000 million-$410.000 million.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com What's Next: PROCEPT BioRobotics's Earnings Preview 
benzinga.com A Peek at PROCEPT BioRobotics's Future Earnings - benzinga.com Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $47 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $50 to $47.
- benzinga.com UBS Initiates Coverage On PROCEPT BioRobotics with Buy Rating, Announces Price Target of $62 UBS analyst Danielle Antalffy initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy rating and announces Price Target of $62.
- benzinga.com B of A Securities Downgrades PROCEPT BioRobotics to Neutral, Lowers Price Target to $38 B of A Securities analyst Craig Bijou downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Neutral and lowers the price target from $55 to $38.
- benzinga.com Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51 Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $56 to $51.